Propiedad y actividad de insiders de Lyell Immunopharma, Inc. (LYEL): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $10.78 |
| Capitalización | $264M |
| Bolsa | NASDAQ |
| País | US |
Operaciones Recientes de Insiders
| Fecha | Insider | Tipo | Acciones | Valor |
|---|---|---|---|---|
| 2026-09-10 | Shook David | S-Sale | 500 | $6K |
| 2026-09-10 | Aguirre Jarrad Mattieu | A-Award | 47,500 | $580K |
| 2026-08-31 | Aguirre Jarrad Mattieu | |||
| 2026-08-31 | Aguirre Jarrad Mattieu | 46,249 | $538K | |
| 2026-08-31 | Aguirre Jarrad Mattieu | 35,000 | $830K | |
| 2026-08-31 | Aguirre Jarrad Mattieu | 15,000 | $288K | |
| 2026-08-21 | Seely Lynn | S-Sale | 9,589 | $149K |
| 2026-08-21 | Hill Stephen J. | S-Sale | 989 | $15K |
| 2026-08-21 | Lee Gary K. | S-Sale | 1,457 | $23K |
| 2026-08-10 | Bulis Veronica Sanchez | S-Sale | 621 | $9K |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $96.7M | $140.4M | $293.8M | $123.6M | $145.6M | $105.6M | $60.2M |
| Inversiones a Corto | $339.4M | $472.2M | $321.0M | $516.6M | $400.6M | $264.9M | $187.0M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $440.3M | $617.5M | $626.3M | $651.3M | $554.7M | $379.6M | $260.9M |
| Inmovilizado Material | $43.7M | $124.1M | $166.6M | $166.3M | $142.3M | $72.9M | $53.6M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $555.6M | $908.3M | $1.13B | $937.6M | $750.0M | $490.9M | $340.1M |
| Cuentas por Pagar | $2.8M | $9.4M | $3.2M | $3.9M | $4.8M | $5.4M | $2.9M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $22.0M | $49.3M | $46.7M | $37.0M | $34.5M | $53.8M | $49.4M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $147.6M | $189.8M | $197.6M | $104.3M | $95.1M | $108.0M | $91.8M |
| Reservas | -$129.7M | -$334.1M | -$584.4M | -$767.5M | -$1.00B | -$1.35B | -$1.62B |
| Patrimonio Neto | $408.1M | $718.4M | $929.8M | $833.3M | $655.0M | $382.8M | $248.2M |
| Deuda Total | $27.5M | $54.6M | $67.8M | $67.7M | $63.2M | $59.0M | $51.0M |
| Deuda Neta | -$408.6M | -$558.0M | -$547.0M | -$572.5M | -$483.1M | -$311.6M | -$196.2M |
| Capital Circulante | $418.2M | $568.3M | $579.5M | $614.3M | $520.2M | $325.8M | $211.5M |
Salud financiera
| Deuda / Patrimonio | 0.16 |
| Ratio corriente | 5.36 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.46 |
Rentabilidad
| Rentabilidad sobre capital | -91.62% |
| Rentabilidad sobre capital invertido | -70.80% |
| Rentabilidad sobre activos | -79.86% |
| Margen bruto | -8537.04% |
| Margen operativo | -711329.63% |
| Margen neto | -920285.19% |
Empresas relacionadas: ACIU · ALDX · ALLO · AMRN · CABA · EDIT · GNLX
Explorar sector: Healthcare · Biotechnology
Más secciones de LYEL: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones